Mohs Surgery for High-Risk Squamous Cell Carcinoma: Managing SCC in Difficult Locations

What Makes SCC Different from BCC When It Comes to Mohs Surgery?

Both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are common non-melanoma skin cancers that can be treated with Mohs surgery. But SCC has distinct biological behaviors that change how Mohs surgeons approach it:

• Metastatic potential: SCC can spread to regional lymph nodes and distant organs in approximately 2–5% of cases overall — and in 30–40% of high-risk or recurrent cases. BCC almost never metastasizes.
• Perineural invasion: SCC has a higher tendency than BCC to spread along nerve pathways (perineural invasion), which can extend the tumor well beyond its visible borders and increases the importance of thorough margin control.
• Immunosuppression risk: Organ transplant recipients develop SCC at dramatically higher rates and with more aggressive behavior — up to 65-fold increased risk in kidney transplant recipients compared with the general population.
• Depth matters more: The deeper an SCC invades, the higher the recurrence and metastasis risk. Tumors deeper than 2 mm are considered high-risk.

These differences mean that for SCC, the stakes of incomplete removal are higher — making the 100% margin examination of Mohs surgery especially valuable for qualifying tumors.

Which SCCs Are Treated with Mohs Surgery?

Not every SCC requires Mohs surgery. According to AAD and ASDS guidelines, the following SCC features are indicators for Mohs:

• Location on the head and neck — especially the face, scalp, ears, lips, and eyelids
• Tumor diameter ≥2 cm on the face, or ≥4 cm on the trunk and extremities
• Invasion depth >2 mm or beyond the dermis (Clark level IV or V on biopsy)
• Poorly differentiated or undifferentiated histology on biopsy
• Perineural or perivascular invasion identified on pathology report
• SCC arising in a scar, chronic wound, or previously irradiated area
• Recurrent SCC — any SCC that has come back after prior treatment
• SCC in an immunocompromised patient (organ transplant, HIV, chronic lymphocytic leukemia)
• SCC arising in non-sun-exposed areas (mucosal surfaces, genitalia) which tend to behave more aggressively

What to Expect During Mohs Surgery for SCC

The surgical process for SCC is the same as for BCC, with a few SCC-specific considerations:

• Initial debulking: Some Mohs surgeons use a curette to scrape away the visible tumor before taking the first Mohs layer. This helps identify the clinical tumor borders more clearly.
• Potentially wider initial margins: Because SCC can have subclinical extensions along nerve pathways, surgeons may take slightly wider initial layers than for BCC.
• More stages may be required: SCC tends to have more irregular growth patterns than nodular BCC. High-risk SCCs on the face may require 2–4 stages on average.
• Perineural tracking: If nerve involvement is found on frozen sections, additional tissue is followed along the nerve path, and the surgeon may consult with a head-and-neck surgeon.
• Sentinel lymph node discussion: For very high-risk SCCs, your surgeon may discuss sentinel lymph node biopsy to check for spread to nearby lymph nodes.

Additional Considerations After Mohs for SCC

After Mohs surgery successfully clears the margins of your SCC, the treatment may not be fully complete depending on the tumor’s features:

• Adjuvant radiation therapy: For cases with perineural invasion involving large named nerves, radiation may be recommended to reduce the risk of tumor tracking along nerve pathways that cannot be fully followed surgically.
• Lymph node surveillance: If your SCC was very large, deeply invasive, or showed perineural involvement, your surgeon may refer you to a head-and-neck surgeon or radiation oncologist to discuss lymph node evaluation.
• Systemic therapy for advanced SCC: Cemiplimab (Libtayo) and pembrolizumab (Keytruda) are FDA-approved immunotherapy drugs for locally advanced or metastatic SCC that cannot be treated with surgery or radiation alone.
• More intensive follow-up: SCC follow-up is typically more intensive than for BCC — quarterly exams for the first year, then semi-annually for several years, with lymph node palpation at every visit.

Recovery After Mohs for SCC

• Recovery follows the same course as any Mohs procedure. The wound is repaired the same day using the method that best balances function and appearance for the specific location.
• Follow your wound care instructions carefully — daily cleaning, petroleum jelly, and a fresh bandage until fully healed.
• Sutures are removed 5–14 days after surgery depending on location.
• Avoid heavy exercise for 2–4 weeks to protect the repair site.
• Protect the healed scar from sun exposure with SPF 30+ sunscreen for at least 12 months.

When to See a Dermatologist

• You have a firm, rough, or crusted skin growth that is growing, bleeding, or not healing within several weeks
• You received a biopsy diagnosis of SCC and want to understand your specific treatment options
• You are an organ transplant recipient — you should have full-body skin exams every 3–6 months
• You notice new lumps under the skin near a previous SCC scar (possible lymph node involvement)
• You have a wound that was previously treated for SCC and is showing signs of returning

Frequently Asked Questions

How does SCC differ from BCC in terms of danger?

BCC almost never spreads beyond the skin, so the primary concern is local tissue damage. SCC, while also generally slow-growing, has a meaningful rate of spread to lymph nodes or internal organs — especially when high-risk features are present. The overall metastasis rate for all SCCs combined is about 2–5%, but that rises steeply for tumors with aggressive features, recurrent disease, or tumors in immunosuppressed patients. This is why high-risk SCC is taken very seriously and why Mohs surgery is favored for the tumors most likely to misbehave.

My biopsy just said “well-differentiated SCC.” Do I still need Mohs?

Not necessarily. Well-differentiated (low-grade) SCCs in non-critical locations are often adequately treated with standard excision. Mohs surgery is primarily indicated when the location is high-risk (face, ears, lips), the tumor is large (≥2 cm on the face), the SCC has returned after prior treatment, or the patient is immunocompromised. Your dermatologist will apply these criteria to your specific situation.

What is the risk that my SCC has already spread?

For the average low-risk SCC on sun-exposed skin, the risk of spread to lymph nodes is about 2–4%. For high-risk SCC — large, deeply invasive, or arising in immunocompromised patients — this rises significantly. Your dermatologist will assess your lymph nodes clinically and may order imaging studies if there is concern. SCC caught and treated before metastasis has an excellent prognosis.

Can Mohs surgery be done on an elderly or medically fragile patient?

Yes. Because Mohs surgery uses only local anesthesia and is performed in an outpatient setting, it is generally very well tolerated even by elderly patients or those with significant medical conditions. There is no general anesthesia involved. For very frail patients, the surgical team will carefully consider wound repair options and may opt for second-intention healing to reduce procedure complexity.

Trusted Resources

• American Academy of Dermatology — Squamous Cell Carcinoma
• Skin Cancer Foundation — SCC
• Mayo Clinic — SCC Treatment
• American College of Mohs Surgery — Patient Information

Always consult a board-certified dermatologist or Mohs surgeon for evaluation and treatment of squamous cell carcinoma. This article is for educational purposes only and does not replace professional medical advice.